Replies to post #114737 on Biotech Values

[DewDiligence]

Another notable feature of MDCO’s settlement is that the contingent damage award does not have a sliding scale based on the number of days prior to 6/15/15 that a generic Angiomax is approved. Thus, “maximum emotional pain” for WilmerHale would be the FDA’s approving the first generic on 6/14/15.